Outcome of Board Meeting dated 14th November, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board approved unaudited financial results for the quarter and half year ended September 30, 2025. On a consolidated basis, revenue from operations grew 29.4% year-on-year in Q2 to ₹6,260.19 lakhs (vs ₹4,836.29 lakhs in Q2 FY25), while H1 FY26 revenue stood at ₹11,597.74 lakhs (up ~17.8% YoY). Consolidated profit after tax rose modestly to ₹362.32 lakhs in Q2 (vs ₹341.44 lakhs), but declined about 6.8% in H1 to ₹689.81 lakhs. Margins came under pressure, with EBITDA margin compressing roughly 300 basis points YoY in H1, driven by higher material costs and other expenses. Standalone results remain very small as the main pharmaceutical business runs through subsidiary Naxpar Pharma, where standalone H1 PAT fell to ₹19.13 lakhs from ₹28.20 lakhs. The statutory auditor (C.N. Patel & Co.) issued a clean, unmodified limited review report on both sets of results.
Strong top-line growth at the consolidated level is a positive sign for the business, but the notable drop in profitability and EBITDA margin compression in H1 FY26 may temper investor enthusiasm. Standalone numbers are not meaningful as the real business sits in the subsidiary, so investors should focus on consolidated metrics.